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The mechanisms of hepatitis C virus (HCV)-associated hepatocarcinogenesis and disease progression 
are unclear.  We previously observed that the expression level of carboxypeptidase B2 (CPB2) gene 
was remarkably suppressed by persistent HCV RNA replication in human hepatoma cell line Li23-
derived cells.  The results of the present study demonstrated that the CPB2 expression in patients with 
chronic hepatitis C was inversely correlated with several risk factors of hepatic ﬁ brosis or steatosis,  
although ectopic CPB2 expression did not suppress the expression of ﬁ brogenic or lipogenic genes.  The 
suppressed CPB2 expression was restored by treatment with 5-azacytidine.  To clarify the mechanism 
underlying this phenomenon,  we analyzed the CPB2 promoter,  and the results revealed that (1) hepa-
tocyte nuclear factor 1 (HNF1),  especially HNF1α,  was essential for the CPB2 promoter,  and (2) CPB2 
promoter was not methylated by persistent HCV RNA replication.  The expression levels of HNF1α and 
HNF1β were also not changed by persistent HCV RNA replication.  These results suggest the existence 
of 5-azacytidine-inducible or -reducible unknown factor(s) that can control the CPB2 expression.  To 
evaluate this idea we performed a microarray analysis,  and several gene candidates corresponding to 
the suggested factor(s) were identiﬁ ed.
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H epatitis C virus (HCV),  an enveloped positive single-stranded RNA (9.6-kb) virus belonging to 
the Flaviviridae family,  is a causative agent of chronic 
hepatitis C,  which frequently progresses to liver cir-
rhosis and hepatocellular carcinoma (HCC) [1-3].  
The understanding of the life cycle of HCV has 
greatly progressed [4] since the development of a cell-
based HCV replicon [5],  genome-length HCV RNA 
replication [6],  and infectious HCV production [7] 
systems,  whereas the mechanisms of HCV-associated 
hepatocarcinogenesis and disease progression are still 
unclear.
　 We developed an HCV replicon [8] and genome-
length HCV RNA replication [9] systems.  Since most 
of the existing HCV replication systems were devel-
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oped using a human hepatoma cell line,  i.e.,  HuH-7-
derived cells,  we developed our HCV replicon and 
genome-length HCV RNA replication system using a 
new human hepatoma cell line,  Li23-derived cells 
[10],  whose gene expression proﬁ le is considerably 
distinct from that of HuH-7-derived cells [11].  In that 
study [10],  we established Li23-derived genome-length 
HCV RNA (O strain of genotype 1b)-replicating cell 
lines,  i.e.,  OL (polyclonal),  OL8 (monoclonal),  OL11 
(monoclonal),  and OL14 (monoclonal) cell lines.  Using 
these cell lines,  we recently demonstrated that long-
term (4 years) cultured HCV RNA-replicating cells 
can be useful for analyses of evolutionary dynamics 
and variations of HCV and for drug resistance analy-
ses [12].
　 During the course of the study,  we speculated that 
the long-term replication of HCV RNA might cause 
irreversible changes in the expression proﬁ les of 
particular genes in host cells.  To test this specula-
tion,  we carried out several cDNA microarray analy-
ses using OL,  OL8,  OL11,  and OL14 cells and their 
long-term (＞2 years) cultured cells,  and we observed 
that the expression level of carboxypeptidase B2 
(CPB2) gene was irreversibly downregulated by long-
term persistent HCV RNA replication [13].  No sig-
niﬁ cant changes in the expression level of CPB2 in the 
long-term (＞ 2 years) cultured cured cells,  from which 
the HCV RNA had been eliminated by interferon 
treatment,  were conﬁ rmed [13].  In addition,  no sig-
niﬁ cant changes in the expression levels of these genes 
by the ectopic expression of HCV proteins were also 
conﬁ rmed [13].
　 CPB2,  known as thrombin-activatable ﬁ brinolysis 
inhibitor [14],  is produced mainly by the liver and 
circulates in plasma as a plasminogen-bound zymogen 
[15].  It has been reported that CPB2 also has an 
anti-inﬂ ammatory function based on its cleavage of 
several proinﬂ ammatory mediators such as C5a and 
osteopontin [16,  17].  Since C5 is known to be a 
quantitative trait gene that modiﬁ es liver ﬁ brogenesis 
in humans [18],  we suspected that the suppression of 
CPB2 expression observed in our earlier study might 
be involved in liver ﬁ brogenesis.  In fact,  the suppres-
sion of CPB2 expression has been reported in patients 
with liver cirrhosis,  although it was not an HCV-
associated phenomenon [19].
　 In addition,  it was reported that CPB2 expression 
is regulated by several transcription factors including 
hepatocyte nuclear factor 1 homeobox A (HNF1α) 
[20].  HNF1α is an important transcription factor for 
the hepatocyte-speciﬁ c expression of albumin,  insulin-
like growth factor 1 and so on [21].  To the best of 
our knowledge,  there is no report regarding the 
relationship between the level of HNF1α expression 
and HCV-associated diseases.  Therefore,  in the pres-
ent study we focused on the relationship between 
CPB2 expression and HNF1α.  We report a novel 
mechanism underlying the suppression of CPB2 
expression that occurs by persistent HCV RNA repli-
cation.
Materials and Methods
　 Cell culture. Li-23-derived OL8 and OL11 
cells harboring genome-length HCV RNA were cul-
tured with medium in the presence of 0.3mg/ml of 
G418 (Genticin,  Invitrogen,  Carlsbad,  CA,  USA) as 
described [13].  In the present study,  these cells were 
renamed according to the length of the culture period;
i.e.,  OL8(0Y),  OL8(0.5Y),  OL8(1Y),  OL8(1.5Y),  and 
OL8(2Y) cells were OL8 cells cultured for 0,  0.5,  1,  
1.5,  and 2 years,  respectively.  Cured cells (OL8c(0Y) 
cells) were also cultured with medium in the absence 
of G418 as described [13].  Two-year cultures of 
OL8c(OY) cells were designated as OL8c(2Y).
　 Reagents. 5-azacytidine (5-azaC) and 4-phenyl-
butyric acid (4-PBA) were purchased from Sigma-
Aldrich (St. Louis,  MO,  USA).  Blasticidin S was 
purchased from Funakoshi (Tokyo).
　 Quantitative reverse transcription-poly-
merase chain reaction (RT-PCR) analysis.
Total RNAs from the cells were prepared using an 
RNeasy extraction kit (Qiagen,  Hilden,  Germany).  
The quantitative RT-PCR analysis for mRNA was 
performed as described [13].  Brieﬂ y,  total RNA 
(1µg) was reverse-transcribed with M-MLV reverse 
transcriptase (Invitrogen) using oligo dT primer 
(Invitrogen).  One-tenth of the cDNA was used for the 
quantitative PCR analysis using a real-time LightCycler 
PCR (Roche Diagnostics,  Basel,  Switzerland).
　 The following primer sets were used for the quan-
titative PCR: collagen type I,  alpha 1 (COL1A1:
ﬁ brogenic gene),  5’-AGACCTGCGTGTACCCCACT
CAG-3’ and 5’-TAGGCCACGCTGTTCTTGCAGTG-3’;
collagen type IV,  alpha 1 (COL4A1: ﬁ brogenic gene),  
5’-AGCACAATGCCCTTCCTGTTCTG-3’ and 
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5’-TGGCGCACTTCTAAACTCCTCCAG-3’; acetyl-
CoA carboxylase alpha (ACC1: lipogenic gene),  
5’-CATCCACTTGGCTGAGCGATTGG-3’ and 
5’-GTTTTCCTCTATTACCGAGTGAACAC-3’ ;
acetyl-CoA carboxylase beta (ACC2: lipogenic gene),  
5’-CGACTCTGTCCTCAAGACCAT-3’ and 5’-TGG
TAGACAGCAGGTGAACG-3’; fatty acid synthase 
(FASN: lipogenic gene),  5’-GAAACTGCAGGAGCT
GTC-3’ and 5’-CACGGAGTTGAGGCGCAT-3’;
stearoyl-CoA desaturase 1 (SCD1: lipogenic gene),  
5 ’ -GGTTTCACTTGGAGCTGTGG -3 ’  and 
5 ’-TTGATGTGCCAGCGGTACT-3 ’ ; HNF1α,  
5 ’ -CTTCACACGCCGGCATCTCAG-3 ’ and 
5’-GTGGAGATGAAGGTCTCGATGAC-3’; HNF1 
homeobox B (HNF1β),  5’-AGCTGCACAGCCCTCA
CCAG-3’ and 5’-GAAGACATGTTGGTGAGTGTA
CTG-3’; actin,  beta (β-actin),  5’-GAAGAGCTACG
AGCTGCCTGAC-3’ and 5’-GTGATCTCCTTCTG
CATCCTGTC-3’.
　 The primer sets for CPB2 and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) were as described 
[13].  Endogenous CPB2 mRNA was quantiﬁ ed using 
the same forward primer as described above and a 
reverse primer (5’-ACGGAAGCAGAATGATAAAA
TCAG-3’) arranged from the 3’ untranslated region of 
CPB2 mRNA.  GAPDH mRNA was quantiﬁ ed as a 
loading control except for the experiments of 5-azaC 
treatment,  in which β-actin mRNA was quantiﬁ ed as a 
loading control.  Experiments were done in triplicate.
　Western blot analysis. The preparation of cell 
lysates,  the sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE),  and the immunoblot-
ting analysis with a PVDF membrane were as 
described [8].  The antibodies used in this study were 
sheep anti-CPB2 antibody (SATAFI-AP; Aﬃ  nity 
Biologicals,  Ancaster,  ON,  Canada),  rabbit poly-
clonal anti-HNF1α antibody (GeneTex,  Hsinchu City,  
Taiwan),  rabbit polyclonal anti-HNF1β antibody 
(Proteintech,  Chicago,  IL,  USA),  and mouse mono-
clonal anti-β-actin antibody (AC-15; Sigma-Aldrich).  
β-actin antibody was used for the loading control.
　 5-azaC and/or 4-PBA treatment. OL8(0Y),  
OL8(2Y),  OL8(3.5Y),  or OL8(4Y) cells were treated 
with 5-azaC (2.5 or 10µM) or 4-PBA (1mM),  or a 
combination of 5-azaC (2.5 or 10µM) and 4-PBA 
(1mM).  Total RNAs prepared from the treated cells 
were subjected to quantitative RT-PCR for CPB2 
mRNA and β-actin mRNA as a control.
　 Gene promoter analysis. Genomic DNAs from 
OL8(0Y) cells were prepared using DNeasy (Qiagen) 
as described [22].  According to the putative tran-
scriptional start site [20],  we used PCR to amplify 
various lengths of 5’ ﬂ anking region containing the 5’ 
end (21bp) of CPB2 (NT_024524.14; －2700,  －989,  
－609,  －200,  －150,  －91,  －75 or －52 to ＋21),  
using KOD-plus DNA polymerase (Toyobo,  Osaka,  
Japan).  The PCR products were inserted into the 
NheI-HindIII site on pGL4.10-luc2 (Promega,  Madison,  
WI,  USA).  pGL4.10-luc2 possessing serially trun-
cated CPB2 promoter and pRL-SV40 (internal control) 
were cotransfected into OL8(0Y) or OL8(2Y) cells by 
FuGENE HD (Promega).  Two days later,  a dual 
luciferase assay was performed as described [22,  
23].  Experiments were done in triplicate.
　 Bisulphite sequencing analysis. We con-
ducted a bisulphite treatment of genomic DNAs from 
OL8(0Y),  OL8(2Y),  or OL8(4Y) cells using a 
MethylEasyTM Xceed Rapid DNA Bisulphite 
Modiﬁ cation Kit (Takara Bio,  Otsu,  Japan).  A set of 
primers (5’-GTTGATTGATTTATAGGAATAAGA
GG-3’ and 5’-TTACCATTTTATCCACCAACTC-3’) 
was used to amplify the CPB2 promoter region (307bp) 
using TaKaRa EpiTaq HS (for bisulﬁ te-treated DNA;
Takara Bio).  The PCR product was inserted into 
T-vector pMD19(Simple) and then subjected to the 
sequencing analysis as described [12].
　 Site direct mutagenesis. Using QuickChange 
mutagenesis (Stratagene,  La Jolla,  CA,  USA) [6],  
we introduced 3 types of mutation into the plasmids 
that were made for the analysis of CPB2 promoter as 
described above.
　 RNA interference. Small interfering RNA 
(siRNA) duplexes targeting HNF1α (M-008215-01-
0005; GE Dharmacon,  Lafayette,  CO,  USA) and 
HNF1β (M-009721-01-0005; GE Dharmacon) were 
chemically synthesized.  Non-targeting siRNA 
(D-001206-13-20) and siRNA targeting Rab18 
(M-010824-00-0005; Thermo Fisher Scientific,  
Waltham,  MA,  USA) were used as controls [24].  
OL8(0Y) cells were transfected with the siRNA 
duplexes using RNAiMAX (Invitrogen).
　 Ectopic gene expression. The open reading 
ﬂ ame (ORF) of CPB2 (NM_001872.3) was ampliﬁ ed by 
PCR using KOD-plus DNA polymerase,  and then the 
PCR product was inserted into MluI-NotI site of 
pCX4bsr.  Retroviral transfer to OL8(2Y) cells and 
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the selection by blasticidin S were performed as 
described [25].  The ORFs of aldehyde dehydroge-
nase 1 family,  member A1 (ALDH1A1; NM_000689.4),  
albumin (ALB; NM_000477.5),  annexin A1 (ANXA1;
NM_000700.1),  ﬁ brinogen gamma chain (FGG;
NM_000509.4),  fibrinogen beta chain (FGB;
NM_005141.4),  tissue factor pathway inhibitor (TFPI;
NM_006287.4),  ﬁ brinogen-like 1 (FGL1; NM_004467.3),  
and alpha-2-HS-glycoprotein (AHSG; NM_001622.2) 
were also ampliﬁ ed by PCR and inserted into pCX-
4bsr as described above.
　 The ORFs of glutathione peroxidase 2 (GPX2;
NM_002083.3),  variable charge,  X-linked 2 (VCX2;
NM_016378.3),  and anterior gradient 2 (AGR2;
NM_006408.3) were ampliﬁ ed by PCR,  and then each 
PCR product was inserted into the EcoRI-MluI site of 
pCX4bsr.  The ORFs of synovial sarcoma,  X break-
point 4 (SSX4; NM_005636.3) and zinc ﬁ nger with 
KRAB and SCAN domains 7 (ZKSCAN7;
NM_018651.3) were also ampliﬁ ed by PCR,  and then 
each PCR product was inserted into the EcoRI-NotI 
site of pCX4bsr.  The constructed plasmid possessing 
GPX2 ORF was transfected into OL8(0Y) cells using 
FuGENE HD.  The other constructed plasmids were 
also transfected into OL8(2Y) cells using FuGENE 
HD.  After culturing for 48h,  total RNAs prepared 
from the cells were subjected to a quantitative 
RT-PCR analysis for CPB2 mRNA.
　 Immunoﬂ uorescence analysis. The intracel-
lular localization of HNF1α was visualized and photo-
graphed under a confocal microscope as described 
[24].
　 mRNA and miRNA microarray analyses.
Total RNAs from OL8(2Y) and those from OL8c(2Y) 
cells treated with or without 5-azaC (10µM) for 1 
week were prepared using an RNeasy kit for the 
cDNA microarray analysis,  and total RNAs from 
OL8(0Y),  OL8(2Y),  OL11(0Y),  and OL11(2Y) cells 
were prepared using the miRNeasy mini kit (Qiagen) 
for the microRNA microarray analysis.  As described 
[10,  22],  both of the array analyses were carried out 
by the Dragon Genomics Center of Takara Bio through 
an authorized Aﬀ ymetrix and Agilent Certiﬁ ed service 
provider,  using the GeneChip Human Genome U133 
Plus 2.0 Array or the Agilent Human miRNA micro-
array (Rel.  16.0).
　 Statistical analysis. The signiﬁ cance of diﬀ er-
ences among groups was determined using Student’s 
t-test with a two-sided test.  P-values ＜0.05 were 
considered signiﬁ cant.
Results
　 The expression level of CPB2, suppressed by 
persistent HCV RNA replication, was inversely 
correlated with the status of hepatic diseases.
In our earlier study we observed that the CPB2 
expression was greatly suppressed by the 2-year per-
sistent HCV RNA replication in Li23-derived cells 
[13].  Here we ﬁ rst investigated the time point during 
the 2 years at which the CPB2 expression was sup-
pressed.  Our quantiﬁ cation of CPB2 mRNA in 
OL8(0Y),  OL8(0.5Y),  OL8(1Y),  OL8(1.5Y),  and 
OL8(2Y) cells revealed that the CPB2 expression was 
signiﬁ cantly suppressed between 6 months and 1 year 
of HCV RNA replication (Fig.  1).  This result sug-
gests that something occurs in the transcriptional 
control mechanism of the host cells by the HCV RNA 
replication for more than 6 months.  Such a persistent 
HCV RNA replication suggested a state of chronic 
hepatitis C,  and using the clinical data and the gene 
expression proﬁ les of 91 patients with chronic hepati-
tis C [26],  we therefore next examined the relation-
ship between several of the patients’ clinical factors 
and their hepatic expression levels of CPB2.
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Fig. 1　 The downregulation of CPB2 expression occurred mainly 
between 6 months and 1 year of persistent HCV RNA replication.  
We quantiﬁ ed the expression level of CPB2 mRNA in OL8(0Y),  
OL8(0.5Y),  OL8(1Y),  OL8(1.5Y),  and OL8(2Y) cells using a real-
time LightCycler PCR.  Experiments were performed in triplicate.  
＊＊p＜0.01.
　 The analysis revealed that the expression level of 
CPB2 was signiﬁ cantly and inversely correlated with 
the patients’ ﬁ brotic stages,  which indicate F1 as mild 
hepatic ﬁ brosis to F4 as cirrhosis (Fig.  2A).  We also 
observed that the expression level of CPB2 was low in 
the patients with a body mass index (BMI) value ＞25,  
which is a risk value for the development of hepatic 
diseases including steatosis (Fig.  2B).  The results of 
our analysis demonstrated that the expression level of 
CPB2 was correlated with the number of platelets 
(Fig.  2C) and inversely correlated with the markers 
of the status of hepatic damage: aspartate transami-
nase (AST; Fig.  2D),  alanine transaminase (ALT;
Fig.  2E),  and gamma-glutamyl transferase (γ-GTP;
Fig.  2F).  These results suggest that the suppression 
of CPB2 expression is involved in the hepatic ﬁ brosis 
or steatosis.
　 However,  the ectopic expression of CPB2 in the 
OL8(2Y) cells (Fig.  3A) did not aﬀ ect the expression 
levels of ﬁ brogenic genes such as COL1A1 and 
COL4A1 (Fig.  3B) or lipogenic genes such as ACC1,  
ACC2,  FASN,  and SCD1 (Fig.  3C),  suggesting that 
the expression levels of these genes are not regulated 
only by CPB2.
　 The suppression of CPB2 expression in long-
term cultured OL8(0Y) cells was cancelled by 
5-azaC treatment. Since the marked suppression 
of CPB2 expression occurred between 6 months and 1 
year of culture,  we ﬁ rst suspected that a somatic 
mutation in the CPB2 locus caused the transcriptional 
suppression.  However,  such a mutation was not 
detected at the 2-kb upstream from the transcription 
initiation site of CPB2 derived from OL8(2Y) cells 
(data not shown).  In addition,  no mutation was 
detected in the ORF of CPB2 including both the 5’- and 
3’ untranslated regions derived from OL8(2Y) cells 
(data not shown).  We therefore speculated that an 
epigenetic alteration such as DNA methylation 
occurred during the long-term culture of OL8(0Y) 
cells.
　 To test this speculation,  we examined the eﬀ ect of 
5-azaC treatment on the CPB2 expression.  Using the 
OL8(0Y),  OL8(2Y),  and OL8(4Y) cells treated with 
5-azaC for 1 week,  we quantiﬁ ed the level of CPB2 
mRNA in these cells by a quantitative RT-PCR analy-
sis,  which revealed that the expression levels of CPB2 
in OL8(2Y) and OL8(4Y) cells were recovered to the 
same level as that of OL8(0Y) cells (Fig.  4A).  We 
also observed that the level of CPB2 expression in 
OL8(0Y) cells was not further elevated by 5-azaC 
treatment (Fig.  4A).  These results suggest that per-
sistent HCV RNA replication suppresses CPB2 
expression through DNA methylation.
　 We further examined the epigenetic eﬀ ect on the 
expression level of CPB2 using OL8(0Y),  OL8(2Y),  
and OL8(3.5Y) cells treated with 5-azaC and/or 
4-PBA (histone deacetylase inhibitor).  The results 
revealed that the treatment with 4-PBA or its combi-
nation with 5-azaC did not aﬀ ect the expression level 
of CPB2 in these cells (Fig.  4B,  C).  These results 
suggest that histone deacetylation is not involved in the 
suppression of CPB2 expression.
　 The CPB2 promoter was not methylated by 
persistent HCV RNA replication. Before the 
detailed analysis of the methylation state of CPB2 
promoter,  we attempted to identify the essential 
domain for CPB2 promoter activity.  Using luciferase 
reporter plasmids containing CPB2 promoters system-
atically truncated from －2700 (Fig.  5A),  we carried 
out the promoter assay in OL8(0Y) cells.  The results 
revealed that the region from －150 to －52 was a 
main domain for CPB2 promoter activity (Fig.  5A).  
Similar results of the promoter assay were also 
obtained using OL8(2Y) and OL8c(0Y) cells (data not 
shown).
　 These ﬁ ndings revealed that the number of CpG 
sites in the region from －150 to －52 was only one (C 
is located at －82).  To clarify whether the methylation 
of this CpG site caused the suppression of CPB2 
expression,  we examined the methylation status of this 
CpG site in OL8(0Y),  OL8(2Y),  and OL8(4Y) cells 
by the bisulphite sequencing method.  We obtained the 
unexpected result that the methylation frequencies for 
C at －82 in the OL8(2Y) and OL8(4Y) cells were 
only 4  and 8 ,  respectively (Fig.  5B),  whereas 
that in the OL8(0Y) cells was 0 .  Taken together,  
these results and those described above suggest that 
the suppression of CPB2 expression by the persistent 
HCV RNA replication is caused by a DNA methyla-
tion event other than the methylation of CPB2 pro-
moter.
　 HNF1 was essential for CPB2 expression, 
but it was not a cause of the suppression of 
CPB2 expression by persistent HCV RNA repli-
cation. In light of the above-described ﬁ ndings,  we 
considered the possibility that the expression of tran-
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scription factor,  which positively controls the CPB2 
expression,  was suppressed by DNA methylation.  In 
this context,  we noticed the HNF1 binding site-like 
sequence in the region from －81 to －69,  which is 
included within our identiﬁ ed main domain (－150 to 
－52) for CPB2 promoter (Fig.  6A).  This sequence 
(wt) shows the diﬀ erence in 2 nucleotides from the 
consensus sequences for the HNF1 binding site (Fig.  
6A).
　 To determine whether the wt sequence functions as 
a main domain for the promoter activity,  we modiﬁ ed 
a wild type of reporter plasmid (－91wt) containing 
the region from －91 to ＋21 of CPB2 promoter,  and 
we created 3 types of mutants (－91mt1 and －91mt2,  
which would diminish HNF1 binding,  and －91mt3,  
which is the same as the consensus sequence) (Fig.  
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Fig. 2　 The expression level of CPB2 was inversely correlated to F-stage,  body mass index (BMI),  and biomarkers of liver health.  The 
hepatic expression levels of CPB2 mRNA in 91 patients with chronic hepatitis C were compared with the patients’ F-stages (A),  BMI (B),  
number of platelets (C),  and AST (D),  ALT (E),  and γ-GTP (F) levels.
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Fig. 3　 The eﬀ ects of ectopic CPB2 expression on the expression levels of hepatic ﬁ brogenic or lipogenic genes.  (A) The ectopic CPB2 
expression in the OL8(2Y) cells.  CPB2 gene was stably and ectopically expressed in OL8(2Y) cells by pCX4bsr retroviral transfer.  The 
Western blot analysis of CPB2 was performed as described in the Materials and Methods.  (B) Quantitative RT-PCR analysis results of 
ﬁ brogenic COL1A1 and COL4A1 mRNAs in OL8(2Y) cells (Control) and OL8(2Y) cells expressing CPB2.  Each mRNA level was calcu-
lated relative to the level in OL8(2Y) cells (Control),  which was assigned a value of 100%.  Experiments were performed in triplicate.  (C) 
Results of the quantitative RT-PCR analysis of lipogenic ACC1,  ACC2,  FASN,  and SCD1 mRNAs in OL8(2Y) cells (Control) and OL8(2Y) 
cells expressing CPB2. The experiments were performed as described in (B).
Fig. 4　 The suppression of CPB2 expression in long-term cultured cells 
was cancelled by 5-azaC treatment.  (A) The suppression of CPB2 mRNAs 
in OL8(2Y) and OL8(4Y) cells were restored by 1-week 5-azaC treatment.  
OL8(2Y) and OL8(4Y) cells were treated with or without 2.5 or 10µM of 
5-azaC for 1 week.  OL8(0Y) cells were used as a control.  A quantitative 
RT-PCR analysis for CPB2 mRNA was carried out as described in the Fig. 
1 legend.  The levels of CPB2 mRNA were normalized to the levels of β-actin 
mRNA.  Experiments were performed in triplicate.  ＊p＜0.05.  (B) Eﬀ ect of 
4-PBA on the CPB2 expression in OL8(3.5Y) cells.  OL8(0Y) and OL8(3.5Y) 
cells were treated with 5-azaC,  4-PBA,  or 5-azaC and 4-PBA for 2 days.  A 
quantitative RT-PCR analysis for CPB2 mRNA was performed as described 
in (A).  The experiments were performed in triplicate.  (C) The eﬀ ect of 
4-PBA on the CPB2 expression in OL8(2Y) cells.  OL8(0Y) and OL8(2Y) cells 
were treated with 5-azaC,  4-PBA,  or 5-azaC and 4-PBA for 2 days after a 
1-week treatment with 5-azaC (10µM) only.  A quantitative RT-PCR analysis 
for CPB2 mRNA was performed as described in (A).  The averages of 
duplicate experiments are shown.
6A).  Using these modiﬁ ed plasmids with a wild type 
(－91wt) and 2 truncated (－75 and －52) plasmids,  
we performed the promoter assay in OL8(0Y) cells.
　 The results revealed that the promoter activities of 
－91mt1 and －91mt2 were completely diminished,  as 
was observed in the other plasmids (－75 and －52),  
whereas the activity of －91mt3 was higher than that 
of －91wt (Fig.  6B).  We obtained similar results 
using a reporter plasmid (－2700wt) containing the 
region from －2700 to ＋21 and 3 types of modiﬁ ed 
plasmids (－2700mt1,  －2700mt2,  and －2700mt3) 
(Fig.  6C).  These results indicate that the HNF1 
binding site-like sequence (from －81 to －69) was 
essential for the CPB2 promoter activity.
　 Since the activity of the －91mt3 or －2700mt3 
increased to approximately twice that of the －91wt 
or －2700wt (Fig.  6B,  C),  we suspected that HNF1 
was truly bound to our identiﬁ ed region (－89 to －
69) of the CPB2 promoter.  To further investigate 
whether HNF1 controls the CPB2 promoter,  we ﬁ rst 
created the HNF1α- and HNF1β-double-knockdown 
OL8(0Y) cells,  because HNF1α and HNF1β were 
known,  and then we performed the promoter assay 
using the wild type and modiﬁ ed plasmids in the 
knockdown cells.  The results revealed that the pro-
moter activity of －91wt or －2700wt was greatly 
decreased in the double-knockdown cells (Fig.  6C),  
demonstrating that HNF1 controls the CPB2 promoter.
　 In this analysis,  we noticed an additional interest-
ing phenomenon: the promoter activity of －2700mt3 
was not decreased in the double-knockdown cells (Fig.  
6C),  suggesting the existence of another HNF1-like 
transcription factor which is able to bind to the HNF1 
consensus sequence in the CPB2 promoter.  In a series 
of promoter assays using these siRNAs,  we found that 
HNF1α or HNF1α and HNF1β,  but not HNF1β,  
controlled the CPB2 promoter (Fig.  6D).  Similar results 
were obtained by the quantitative RT-PCR analysis for 
CPB2 mRNA in the HNF1α and/or HNF1β-knock-
down OL8(0Y) cells (Fig.  6E).  In that analysis,  we 
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Fig. 5　 CPB2 promoter in 
OL8(0Y),  OL8(2Y),  and OL8(4Y) 
cells was not methylated.  (A) 
Results of the CPB2 promoter analy-
sis using a luciferase reporter assay.  
DNA fragments of various lengths 
(－2700,  －989,  －609,  －200,  －
150,  －91,  or －52 to ＋21) of the 
CPB2 promoter region were inserted 
upstream of a ﬁ reﬂ y luciferase gene 
in pGL4.10-luc2.  DNA transfection 
and dual luciferase assays using 
OL8(0Y) cells were performed as 
described in the Materials and 
Methods.  The results of the relative 
luciferase activity calculated using 
the level of luciferase activity in the 
longest (－2700 to ＋21) plasmid 
assigned as 100% are shown.  The 
lysate of cells transfected with 
pGL4.10-luc2 was used as a control 
(－).  Experiments were done in tripli-
cate.  (B) DNA methylation analysis 
of the CPB2 promoter region.  The 
bisulphite sequencing of the CPB2 
promoter region derived from 
OL8(0Y),  OL8(2Y),  and OL8(4Y) 
cells was performed as described in 
the Materials and Methods.
observed that the CPB2 mRNA level was signiﬁ cantly 
but weakly decreased in the HNF1β-knockdown cells,  
although no suppression of CPB2 mRNA was observed 
in the Rab18 (the component required for HCV assem-
bly [24])-knockdown cells used as a control (Fig.  6E).
　 The quantitative RT-PCR analysis for HNF1α,  
HNF1β,  or Rab18 mRNA demonstrated an eﬀ ective 
knockdown of each gene’s expression in the OL8(0Y) 
cells transfected with the corresponding siRNA(s) 
(data not shown).  Taking this ﬁ nding together with our 
other results,  we conclude that HNF1α acts more 
preferentially than HNF1β on the CPB2 expression,  
although it is regulated by not only HNF1α but also 
HNF1β.  We therefore hypothesized that HNF1 func-
tion is suppressed by persistent HCV RNA replica-
tion.  However,  at both the mRNA and protein levels,  
HNF1α and HNF1β were not suppressed in OL8(2Y) 
or OL8(4Y) cells in comparison with OL8(0Y) cells 
(Fig.  7A,  B).  The subcellular localization of HNF1 
was also not diﬀ erent between OL8(0Y) cells and 
OL8(2Y) or OL8(4Y) cells (Fig.  7C).  These results 
suggest that 5-azaC-induced or -reduced some factor(s) 
other than HNF1 suppressed or induced by persistent 
HCV RNA replication causes the marked suppression 
of CPB2 expression.
　 Selection of candidate genes underlying the 
5-azaC-induced restoration of suppressed CPB2 
expression. To identify the gene(s) underlying the 
restoration of suppressed CPB2 expression by the 
treatment with 5-azaC,  we performed a cDNA micro-
array analysis using OL8(2Y) cells treated with or 
without 5-azaC for 1 week.  As a control analysis,  
OL8c(2Y) cells treated with or without 5-azaC were 
also used.  In these analyses,  we hypothesized that 
there were 2 types of candidate genes.  The ﬁ rst type 
of candidate is the gene(s) which act as a suppressor 
of CPB2 expression and whose expression is reduced 
by 5-azaC treatment.  The expression level of this type 
of gene should be relatively low in OL8(0Y),  
OL8c(0Y),  OL8c(2Y),  5-azaC-treated OL8(2Y),  and 
5-azaC-treated OL8c(2Y) cells in comparison with 
OL8(2Y) cells.  As a result of these analyses,  only one 
gene,  GPX2,  was revealed as a candidate gene in this 
ﬁ rst category (Table 1).
　 The second type of candidate is the gene(s) that act 
as a trap agent of the suppressor for CPB2 expression 
and whose expression is induced by 5-azaC treatment.  
The expression level of this type of gene should be 
relatively high in OL8(0Y),  OL8c(0Y),  OL8c(2Y),  
5-azaC-treated OL8(2Y),  and 5-azaC-treated OL8c(2Y) 
cells in comparison with OL8(2Y) cells.  As a result of 
our analyses,  13 genes were identiﬁ ed as candidate 
genes in the second category (Table 1).  As a matter of 
course,  CPB2 was also identiﬁ ed as a member of the 
second category (Table 1).
　 To further evaluate these 14 candidate genes,  we 
examined the eﬀ ects of the transient ectopic expres-
sion of the genes on CPB2 expression.  Each candidate 
gene was ectopically and transiently expressed in 
OL8(2Y) cells or OL8(0Y) cells (only GPX2),  and then 
we checked whether the CPB2 expression was induced 
or suppressed (only GPX2) by performing a quantita-
tive RT-PCR analysis.  We conﬁ rmed the ectopic 
expression of each candidate gene in OL8(2Y) or 
OL8(0Y) cells by a Western blot analysis,  although we 
failed to detect FGG and GPX2 (data not shown).  We 
were unfortunately not able to identify the gene that 
significantly influenced the CPB2 expression 
(Fig.  8A,  8B).  These results suggest that plural 
genes,  not a single gene,  are required for the restora-
tion of suppressed CPB2 expression by 5-azaC treat-
ment.
Discussion
　 The results of the present study demonstrated that 
the expression of CPB2 that was severely suppressed 
by persistent HCV RNA replication was restored by 
treatment with a demethylating agent,  5-azaC.  Our 
ﬁ ndings also revealed that the methylation of the CPB2 
promoter was not a cause of the suppression of CPB2 
expression.  Although our data demonstrated that 
HNF1 (preferentially HNF1α rather than HNF1β) was 
essential for CPB2 expression,  HNF1 was also not a 
cause of the suppression of CPB2 expression.  These 
results suggest that the suppression of CPB2 expres-
sion was caused by the methylation of certain gene(s) 
other than HNF1.  Microarray analyses based on this 
hypothesis identiﬁ ed several gene candidates,  although 
the identiﬁ cation of the actual gene(s) was not achieved.
　 Because the remarkable suppression of CPB2 
expression occurred between 6 months and 1 year of 
HCV RNA replication,  we were interested in the 
expression level of hepatic CPB2 in patients with 
chronic hepatitis C.  Our ﬁ ndings indicated that the 
expression level of CPB2 was inversely correlated with 
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several risk factors for hepatic ﬁ brosis or steatosis.  
However,  we did not observe that CPB2 expression 
suppressed the expression levels of ﬁ brogenic or lipo-
genic genes.  These results suggest that the expression 
of these genes is not controlled by single factor like 
CPB2,  and that several factors including CPB2 par-
ticipate in their transcriptional regulation.
　We also observed that the hepatic CPB2 expression 
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Fig. 6　 HNF1 was essential for CPB2 promoter activity.  (A) Nucleotide sequence alignment of the HNF1-binding site in the reporter 
plasmids (wt,  mt1,  mt2,  and mt3) used in this study.  Nucleotides diﬀ ering from the consensus sequences are shown.  N is equivalent to 
A,  G,  C,  or T,  and W is equivalent to A or T.  (B) Luciferase reporter assay using CPB2 mutant promoters.  The assay was performed as 
described in the Fig. 5A legend.  The results of the relative luciferase activity calculated using the level of luciferase activity in the plasmid 
－91wt assigned as 100% are shown.  Experiments were done in triplicate.  (C) Luciferase reporter assay using HNF1-knockdown OL8(0Y) 
cells.  OL8(0Y) cells were treated with 5nM of siRNAs targeting HNF1α and HNF1β at 1 day before the transfection of reporter plasmids 
containing the CPB2 promoter (－91wt and －2700 to ＋21 with wt,  mt1,  mt2,  or mt3).  The luciferase assay was performed as described 
in the Fig. 5A legend.  The relative luciferase activity was calculated using the level of luciferase activity in the non-targeting siRNA-treated 
cells (siControl) transfected by plasmid －91wt assigned as 100%.  Experiments were done in triplicate.  (D) Luciferase CPB2 promoter 
assay using HNF1α- or/and HNF1β-knockdown OL8(0Y) cells.  The luciferase reporter assay using the reporter plasmid containing the 
CPB2 promoter (－91 to ＋21 with wt) was performed as described in (C).  ＊＊p＜0.01. (E) Eﬀ ects of siRNAs targeting HNF1α or/and HNF1
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after the transfection,  the expression level of CPB2 was measured by quantitative RT-PCR.  ＊p＜0.05,  ＊＊p＜0.01.
decreased with the number of platelets.  Although it is 
known that CPB2 is also expressed in platelets [27] 
and the number of platelets decreases according to the 
progress of HCV-associated ﬁ brosis [28],  the sup-
pression of hepatic CPB2 expression would not be 
dependent on the decrease in the number of platelets.
　 As we originally hypothesized,  we demonstrated 
that CPB2 expression was suppressed by persistent 
HCV RNA replication through DNA methylation,  
which caused an epigenetic alteration of gene expres-
sion.  Nevertheless,  our ﬁ ndings unexpectedly demon-
strated that the essential region of CPB2 promoter was 
not methylated.  Based on our ﬁ ndings,  we considered 
a novel mechanism in which the suppression of CPB2 
expression was caused by unknown factor(s) whose 
promoter region was methylated by persistent HCV 
RNA replication.  However,  in this study we observed 
that HNF1,  especially HNF1α,  controlled the CPB2 
expression.  This ﬁ nding is consistent with the previ-
ous report suggesting the participation of HNF1α in 
the control of CPB2 promoter activity in HepG2 cells 
[20].  However,  our results clariﬁ ed that HNF1α or 
HNF1β was not our suggested factor(s).
　 In this context,  we obtained an interesting result 
in the analysis of CPB2 promoter using the reporter 
possessing an HNF1 consensus sequence (－2700mt3 
in Fig.  6C).  The activity of this reporter did not 
decrease in either the HNF1α- or HNF1β-knockdown 
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Fig. 7　 The HNF1 expression was not aﬀ ected by persistent HCV RNA replication.  (A) The expression levels of HNF1α and HNF1β 
mRNAs in OL8(0Y),  OL8(2Y),  and OL8(4Y) cells.  Quantitative RT-PCR was performed as described in the Fig. 1 legend.  (B) The expres-
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Table 1　 The candidate genes which may regulate CPB2 expression
mRNA expression
OL8(2Y) OL8c(2Y)
－ 5-azaC fold － 5-azaC fold
Downregulated gene
GPX2 833 178 0.21 223 13 0.06
Upregulated genes
　ALDH1A1 4 1,197 340 1,792 3,186 1.8
　AGR2 78 8,755 110 757 5,981 7.9
　VCX2 42 4,176 100 999 5,676 5.7
　ALB 460 13,181 29 8,209 18,533 2.3
　SSX4 24 476 20 931 1,183 1.3
　ANXA1 27 508 19 940 1,814 1.9
　FGG 51 955 19 515 1,343 2.6
　FGB 46 796 17 370 1,173 3.2
　TFPI 48 594 14 684 2,730 4.0
　FGL1 103 1,243 12 1,562 3,820 2.4
　AHSG 604 4,333 7.2 4,719 5,274 1.1
　CPB2 686 4,021 5.9 3,377 4,165 1.2
　ZKSCAN7 39 207 5.3 281 319 1.1
The signal intensity of candidate genes in human genome U133 Plus 2.0 array.
The gray box means that it was judged as no expression.
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Fig. 8　 The eﬀ ect of the ectopic expression of 14 candidate genes on the CPB2 expression.  (A) The eﬀ ect of the ectopic expression of 
5-azaC-suppressed GPX2 on CPB2 expression.  The ORF of GPX2 was inserted into pCX4bsr encoding HA-tagged protein.  The plasmid 
was then transfected into OL8(0Y) cells as described in the Materials and Methods.  The quantitative RT-PCR analysis for CPB2 mRNA 
was carried out as described in the Fig. 1 legend.  The expression level of CPB2 mRNA was normalized to the levels of GAPDH mRNA.  
Experiments were performed in triplicate.  (B) The eﬀ ect of the ectopic expression of 13 5-azaC-induced genes on CPB2 expression.  The 
preparation of expressing plasmid for each candidate gene,  except for ANXA1 and CPB2,  and the ectopic expression of each gene in 
OL8(2Y) cells were carried out as described in the Materials and Methods.  The quantitative RT-PCR analysis for CPB2 mRNA was carried 
out as described in the Fig. 1 legend.  The ORF of ANXA1 and CPB2 was inserted into pCX4bsr without HA-tag.  The endogenous CPB2 
mRNA expression in CPB2-expressed OL8(2Y) cells was compared with that in OL8(2Y) cells as described in the Materials and Methods.
cells,  suggesting that some other HNF1-like tran-
scription factor binds to the HNF1 consensus 
sequence of －2700mt3 and enhances the promoter 
activity.  However,  such an HNF1-like factor would 
not be involved in the suppression of CPB2 expression,  
because this factor should be not able to bind to the 
wild-type sequence (Fig.  6A) of CPB2 promoter.  We 
therefore speculate that the suppression of CPB2 
expression by persistent HCV RNA replication is 
caused by an unexpected or complex mechanism.
　 Our present ﬁ ndings showed that the suppression 
of CPB2 expression by persistent HCV RNA replica-
tion required more than 6 months,  which suggests that 
some accumulations of changes in the host factor(s) 
must be important for the suppression.  With the goal 
of ﬁ nding the host factor(s) involved in the suppression 
of CPB2 expression,  we carried out a microarray 
analysis using total RNAs prepared from the cells 
treated with or without 5-azaC,  and we were able to 
identify several candidate genes.  Although the objec-
tive factor was not revealed by our experiments using 
the individual candidate genes,  we suspect that mul-
tiple factors are involved in the HCV-induced suppres-
sion of CPB2 expression.
　 Since it is likely that there are objective genes 
among the candidate genes identiﬁ ed in this study,  
further analysis is needed to clarify this speculation.  
As an alternative possibility,  we speculate that certain 
miRNA(s) participate in the suppression of CPB2 
expression.  In this context,  we checked the results of 
the miRNA microarray analysis in the case of 
OL8(0Y) cells versus OL8(2Y) cells and OL11(0Y) 
cells versus OL11(2Y) cells,  because the severe sup-
pression of CPB2 expression had been observed in 
OL11(2Y) cells in addition to OL8(2Y) cells [13].  
Although we found several miRNA species whose 
expression levels were altered by a 2-year replication 
of HCV RNA (Table 2),  we could not ﬁ nd the miRNA 
candidates that may control CPB2 or HNF1.  In addition,  
the results of the microarray analysis revealed that the 
expression levels of most of the commonly upregulated 
miRNAs seemed to be too low to aﬀ ect other gene 
expressions (Table 2).
　 Although we were unable to completely elucidate 
the mechanism underlying the suppression of CPB2 
expression,  the present clariﬁ cation of the mechanism 
contributes to the understanding of the mechanism by 
which persistent HCV replication irreversibly changes 
the gene expression proﬁ le of host cells.  Our ﬁ ndings 
will also contribute to the elucidation of the mecha-
nism of HCV-induced hepatocarcinogenesis.
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Table 2　 MicroRNAs whose expression levels were commonly altered both comparisons of OL8(0Y) versus OL8(2Y) cells and OL11(0Y) 
versus OL11(2Y) cells
miRNA expression
OL8 series OL11 series
OL8(0Y) OL8(2Y) fold OL11(0Y) OL11(2Y) fold
Upregulated miRNAs
　miR-1914＊ 0.1 7.5 75 0.1 11 110
　miR-4298 0.1 5.1 51 0.1 12 120
　miR-4270 0.1 3.4 34 0.1 8.5 85
　miR-3679-5p 0.1 3.7 37 0.1 8.5 80
　miR-378 0.1 5.6 56 0.1 3.6 36
　miR-2116＊ 0.1 5.0 50 0.1 2.3 23
　miR-1246 102 162 1.6 50 166 3.1
　miR-1268 5.2 9.1 1.7 4.4 13 3.0
　miR-2861 15 24 1.6 14 29 2.1
Downregulated miRNAs
　miR-34a 32 15 0.46 35 17 0.49
　miR-22 190 89 0.47 223 108 0.49
The signal intensity in Human miRNA Rel16.0 array of miRNAs,  whose expression levels were commonly upregulated at a ratio of more 
than 1.5 or commonly downregulated at a ratio of less than 0.5,  were listed.
The gray box means that it was judged as no expression.
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